Where are all the longs ? dfcaf always had some informative info....any words ? on action. I have been lonfg the stock but , truly not pleased with shareholder value and transparency of transactions. Basically the ceo
• Loxo's collaboration with Array BioPharma continues to generate compelling and differentiated chemical matter. Loxo has used its multi-target, prioritize-by-success collaboration structure to focus on RET and FGFR.
Clinical Validation for LOXO-101 Published in Cancer Discovery
dcaf7 what's your opinion, where does arry go from here ? There pipeline is still one of the deepest out there for a sub 10.00 stock. Buyout ?
RIGHT ON the money , biotech, somebodies been buying the dip all morning, Would not be surprised if it closes green
been watching the chart and volume last 4 weeks , imo the mm's are taking out your stop losses with minimal volume, When arry explodes it will move a lot higher (% wise) than if it were trading in the 8.00 range Stay patience folks. Please listen to the last CC before you start trying to BS this board
Take a look at JAZZ chart, the intuitions bought up the whole float years ago when it was sub $10.00, it actually traded in the .60 range around 2009. My FIRM belief is the institutions are now well positioned to run ARRY in the same manner with 100% intuitional ownership of the float. ALl you need is patience and a catalyst as our infamous CEO would say lol
1) Yesterdays SEC 8K filing aroused my suspicious, besides increasing their cash position, it moved 33 employees to a new company, the other option would be laying off all unneeded employees. Especially if the acquirer already has a (CMC) Chemistry, Manufacturing and Controls Division . For "INSTATANCE" AstraZeneca already has a CMC Unit, no need to duplicate . I can see the acquirer absorbing the remainder of the ARRAY employees (150).
2) With Institutional Ownership at 102% of float , makes me wonder what does "ALL" the big money know that the retail investor is not aware of ? The last stock I owned with 90% institutional Ownership was HGSI and it was bought out shortly there after.
Of course this is just my humble opinion, time will tell. Like most of you, I rather see the pipeline mature and commercialize their products, than a buyout in the $18.00-$22.00 range.
Opinions ? Ideas ?
MEK162 shows signs of clinical efficacy in pts with biliary tract cancer MEK162 has an acceptable safety profile at 60 mg BID Central serous-like retinopathy was manageable with dose modifications MEK162 has desirable PK propertiesthat were equivalent to that observed in prior studies An additional expansion cohort is ongoing in ptswith KRAS-or BRAF-mutant metastatic colorectal cancer
on the ASCO Website, you might also be able to google it. Waiting for a BIG Monday /Tuesday